Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibronectin Extra-Domain A (EDA)
- Target
- EDA
- Molecular classification
- Extracellular matrix protein domain, Alternatively spliced exon
01
Overview
Fibronectin extra-domain A (EDA), also known as EIIIA, is an alternatively spliced segment of the fibronectin (FN) protein. It is upregulated during tissue injury, wound healing, fibrosis, chronic inflammation, atherosclerosis, and cancer progression. EDA-FN modulates matrix assembly and cell signaling, and its expression is associated with disease severity in asthma, fibrosis, and cancer, making it a therapeutic target. EDA interacts with TLR4 to promote inflammatory gene expression. Therapies targeting EDA-FN are being developed.
- Other names
- EIIIAEDA-FNExtra Domain ACellular FN containing extra-domain A
02
Mechanism of action
Therapeutic strategies include CAR-T cell therapy targeting EDA-FN in tumors, aiming to eliminate cancer cells expressing this isoform in the ECM.
03
Biological functions
Cell adhesionCell migrationCell growthCell differentiationMatrix assemblyCell signalingFibroblast activationMyofibroblast differentiationInflammatory response
04
Disease associations
AsthmaFibrosisCancerAtherosclerosisChronic inflammationWound healingTissue injury
05
Safety considerations
Potential for off-target effects if CAR-T cells or other therapies targeting EDA-FN also affect normal tissues expressing low levels of the protein.Risk of cytokine release syndrome (CRS) and other immune-related adverse events associated with CAR-T cell therapy
06
Biomarkers
EDA-FN expression levels in tissue or plasma as a diagnostic or prognostic marker in cancer, fibrosis, or cardiovascular diseaseEDA-FN expression as a predictive biomarker for response to CAR-T cell therapy
Beyond the preview
Go deeper on Fibronectin Extra-Domain A (EDA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fibronectin Extra-Domain A (EDA).